Description
COEMPAKEN 12.5/500mg Tablets are a fixed-dose combination medication specifically formulated for the comprehensive management of Type 2 Diabetes Mellitus. Each tablet contains Empagliflozin 12.5mg, a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor, and Metformin HCl 500mg, a biguanide. Empagliflozin works by helping the kidneys remove more glucose from the bloodstream, leading to lower blood sugar levels, and also offers significant cardiovascular and renal benefits. Metformin reduces glucose production by the liver and improves insulin sensitivity in the body’s cells. This synergistic action provides dual control over blood sugar, making COEMPAKEN an effective adjunct to diet and exercise. Beyond glycemic control, it helps reduce the risk of cardiovascular death and hospitalization for heart failure in adults with Type 2 Diabetes, and can also offer renal protection. Use strictly as prescribed by a healthcare professional.
